KRAS and neoplasm: This distribution reflected a major contribution from Arg1450 truncations, which were strongly associated with KRAS-activating mutations, occurring in 168 out of 509 (33%) KRAS-mutant tumours compared with in 51 out of 443 (11.5%) KRAS WT tumours.